Anti-amyloid effects of small molecule Aβ-binding agents in PS1/APP mice

Letters in Drug Design and Discovery

Volumn 6, Issue 6, 2009, Pages 437-444

  Cohen, A D ^a   Ikonomovic, M D ^a   Abrahamson, E E ^a   Paljug, W R ^a   DeKosky, S T ^a   Lefterov, I M ^a   Koldamova, R P ^a   Shao, L ^a   Debnath, M L ^a   Mason, N S ^a   Mathis, C A ^a   Klunk, W E ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Alzheimer's disease; Amyloid ; Congo Red; Methoxy X04; Transgenic mice

Indexed keywords

1 (3',4 HYDROXYSTYRYL) 4 (3' METHOXY 4' HYDROXYSTYRYL) BENZENE; 1,4 BIS HYDROXYSTYRYL 2 METHOXYBENZENE; 4 [(3' CARBOXY 4' HYDROXYPHENYL) 1,3 BUTADIENYL]BENZENE; AMYLOID BETA PROTEIN[1-40]; AMYLOID PRECURSOR PROTEIN; ANISOLE; BENZENE; CONGO RED; PRESENILIN 1; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BRAIN; CONTROLLED STUDY; DRUG BINDING; DRUG MECHANISM; DRUG STRUCTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE MUTATION; HISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENICS;

EID: 69549092217     PISSN: 15701808     EISSN: None     Source Type: Journal    
DOI: 10.2174/157018009789057526     Document Type: Article

References (38)

1. Hardy, J.; Allsop, D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol. Sci., 1991, 12, 383-388.
2. Hardy, J. A.; Higgins, G. A. Alzheimer's disease: the amyloid cascade hypothesis. Science, 1992, 256(5054), 184-185.
3. Hardy, J.; Duff, K.; Hardy, K. G.; Perez-Tur, J.; Hutton, M. Genetic dissection of Alzheimer's disease and related dementias: amyloid and its relationship to tau. Nat. Neurosci., 1998, 1(5), 355-358.
4. Tanzi, R. E.; Kovacs, D. M.; Kim, T. W.; Moir, R. D.; Guenette, S. Y.; Wasco, W. The gene defects responsible for familial Alzheimer's disease. Neurobiol. Dis., 1996, 3(3), 159-168. (Pubitemid 26391319)
5. Price, D. L.; Sisodia, S. S. Mutant genes in familial Alzheimer's disease and transgenic models. Annu. Rev. Neurosci., 1998, 21, 479-505. (Pubitemid 28150671)
6. Xia, M. Q.; Bacskai, B. J.; Knowles, R. B.; Qin, S. X.; Hyman, B. T. Expression of the chemokine receptor CXCR3 on neurons and the elevated expression of its ligand IP-10 in reactive astrocytes: in vitro ERK1/2 activation and role in Alzheimer's disease. J. Neuroimmunol., 2000, 108(1-2), 227-235.
7. Schenk, D.; Barbour, R.; Dunn, W.; Gordon, G.; Grajeda, H.; Guido, T.; Hu, K.; Huang, J.; Johnson-Wood, K.; Khan, K.; Kholodenko, D.; Lee, M.; Liao, Z.; Lieberburg, I.; Motter, R.; Mutter, L.; Soriano, F.; Shopp, G.; Vasquez, N.; Vandevert, C.; Walker, S.; Wogulis, M.; Yednock, T.; Games, D.; Seubert, P. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature, 1999, 400(6740), 173-177. (Pubitemid 29327547)
8. Pollack, S. J.; Sadler, I. I.; Hawtin, S. R.; Tailor, V. J.; Shearman, M. S. Sulfonated dyes attenuate the toxic effects of beta-amyloid in a structure-specific fashion. Neurosci. Lett., 1995, 95(3), 211-214.
9. Pollack, S. J.; Sadler, I. I. J.; Hawtin, S. R.; Tailor, V. J.; Shearman, M. S. Sulfated glycosaminoglycans and dyes attenuate the neurotoxic effects of β-amyloid in rat PC12 cells. Neurosci. Lett., 1995, 184, 113-116.
10. Kanski, J.; Sultana, R.; Klunk, W.; Butterfield, D. A. Antioxidant activity of X-34 in synaptosomal and neuronal systems. Brain Res., 2003, 988(1-2), 173-179.
11. Lim, G. P.; Chu, T.; Yang, F.; Beech, W.; Frautschy, S. A.; Cole, G. M. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J. Neurosci., 2001, 21(21), 8370-8377.
12. Yang, F.; Lim, G. P.; Begum, A. N.; Ubeda, O. J.; Simmons, M. R.; Ambegaokar, S. S.; Chen, P. P.; Kayed, R.; Glabe, C. G.; Frautschy, S. A.; Cole, G. M. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J. Biol. Chem., 2005, 280(7), 5892-5901.
13. Shoba, G.; Joy, D.; Joseph, T.; Majeed, M.; Rajendran, R.; Srinivas, P. S. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med., 1998, 64(4), 353-356.
14. Garcea, G.; Berry, D. P.; Jones, D. J.; Singh, R.; Dennison, A. R.; Farmer, P. B.; Sharma, R. A.; Steward, W. P.; Gescher, A. J. Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiol. Biomarkers Prev., 2005, 14(1), 120-125.
15. Garcea, G.; Jones, D. J.; Singh, R.; Dennison, A. R.; Farmer, P. B.; Sharma, R. A.; Steward, W. P.; Gescher, A. J.; Berry, D. P. Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration. Br. J. Cancer, 2004, 90(5)1011-1015.
16. Klunk, W. E.; Bacskai, B. J.; Mathis, C. A.; Kajdasz, S. T.; McLellan, M. E.; Frosch, M. P.; Debnath, M. L.; Holt, D. P.; Wang, Y.; Hyman, B. T. Imaging Abeta plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative. J. Neuropathol. Exp. Neurol., 2002, 61(9), 797-805.
17. Kurt, M. A.; Davies, D. C.; Kidd, M.; Duff, K.; Rolph, S. C.; Jennings, K. H.; Howlett, D. R. Neurodegenerative changes associated with beta-amyloid deposition in the brains of mice carrying mutant amyloid precursor protein and mutant presenilin-1 transgenes. Exp. Neurol., 2001, 171(1), 59-71. (Pubitemid 32848445)
18. Klunk, W. E.; Debnath, M. L.; Pettegrew, J. W. Development of small molecule probes for the beta-amyloid protein of Alzheimer's disease. Neurobiol. Aging, 1994, 15(6), 691-698.
19. Duff, K.; Eckman, C.; Zehr, C.; Yu, X.; Prada, C. M.; Perez-tur, J.; Hutton, M.; Buee, L.; Harigaya, Y.; Yager, D.; Morgan, D.; Gordon, M. N.; Holcomb, L.; Refolo, L.; Zenk, B.; Hardy, J.; Younkin, S. Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature, 1996, 383(6602), 710-713. (Pubitemid 26360645)
20. Hsiao, K.; Chapman, P.; Nilsen, S.; Eckman, C.; Harigaya, Y.; Younkin, S.; Yang, F.; Cole, G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science, 1996, 274(5284), 99-102. (Pubitemid 26332733)
21. Koldamova, R. P.; Lefterov, I. M.; Staufenbiel, M.; Wolfe, D.; Huang, S.; Glorioso, J. C.; Walter, M.; Roth, M. G.; Lazo, J. S. The liver X receptor ligand T0901317 decreases amyloid beta production in vitro and in a mouse model of Alzheimer's disease. J. Biol. Chem., 2005, 280(6), 4079-4088.
22. Watson, R. E., Jr.; Wiegand, S. J.; Clough, R. W.; Hoffman, G. E. Use of cryoprotectant to maintain long-term peptide immunoreactivity and tissue morphology. Peptides, 1986, 7(1), 155-159.
23. Ikonomovic, M. D.; Uryu, K.; Abrahamson, E. E.; Ciallella, J. R.; Trojanowski, J. Q.; Lee, V. M.; Clark, R. S.; Marion, D. W.; Wisniewski, S. R.; DeKosky, S. T. Alzheimer's pathology in human temporal cortex surgically excised after severe brain injury. Exp. Neurol., 2004, 190(1), 192-203.
24. Styren, S. D.; Hamilton, R. L.; Styren, G. C.; Klunk, W. E. X-34, a fluorescent derivative of Congo red: a novel histochemical stain for Alzheimer's disease pathology. J. Histochem. Cytochem., 2000, 48(9), 1223-1232.
25. Franklin, K. B. J.; Paxinos, G. The mouse brain in stereotaxic coordinates; Academic Press: San Diego, 1997.
26. Fishman, C. E.; Cummins, D. J.; Bales, K. R.; DeLong, C. A.; Esterman, M. A.; Hanson, J. C.; White, S. L.; Paul, S. M.; Jordan, W. H. Statistical aspects of quantitative image analysis of betaamyloid in the APP(V717F) transgenic mouse model of Alzheimer's disease. J. Neurosci. Methods, 2001, 108(2), 145-152.
27. Lambert, M. P.; Barlow, A. K.; Chromy, B. A.; Edwards, C.; Freed, R.; Liosatos, M.; Morgan, T. E.; Rozovsky, I.; Trommer, B.; Viola, K. L.; Wals, P.; Zhang, C.; Finch, C. E.; Krafft, G. A.; Klein, W. L. Diffusible, nonfibrillar ligands derived from Abeta1- 42 are potent central nervous system neurotoxins. Proc. Nat. Acad. Sci. USA, 1998, 95(11), 6448-6453.
28. Cleary, J. P.; Walsh, D. M.; Hofmeister, J. J.; Shankar, G. M.; Kuskowski, M. A.; Selkoe, D. J.; Ashe, K. H. Natural oligomers of the amyloid-[beta] protein specifically disrupt cognitive function. Nat. Neurosci., 2005, 8(1), 79-84.
29. Walsh, D. M.; Klyubin, I.; Fadeeva, J. V.; Cullen, W. K.; Anwyl, R.; Wolfe, M. S.; Rowan, M. J.; Selkoe, D. J. Naturally secreted oligomers of amyloid [beta] protein potently inhibit hippocampal long-term potentiation in vivo. Nature, 2002, 416(6880), 535-539.
30. Shankar, G. M.; Li, S.; Mehta, T. H.; Garcia-Munoz, A.; Shepardson, N. E.; Smith, I.; Brett, F. M.; Farrell, M. A.; Rowan, M. J.; Lemere, C. A.; Regan, C. M.; Walsh, D. M.; Sabatini, B. L.; Selkoe, D. J. Amyloid-[beta] protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med., 2008, 14(8), 837-842.
31. Klunk, W. E.; Pettegrew, J. W.; Abraham, D. J. Quantitative evaluation of congo red binding to amyloid-like proteins with a beta-pleated sheet conformation. J. Histochem. Cytochem., 1989, 37(8), 1273-1281.
32. Klunk, W. E.; Jacob, R. F.; Mason, R. P. Quantifying amyloid by Congo red spectral shift assay. Methods Enzymol., 1999, 309, 285-305.
33. Walsh, D. M.; Klyubin, I.; Shankar, G. M.; Townsend, M.; Fadeeva, J. V.; Betts, V.; Podlisny, M. B.; Cleary, J. P.; Ashe, K. H.; Rowan, M. J.; Selkoe, D. J. The role of cell-derived oligomers of Abeta in Alzheimer's disease and avenues for therapeutic intervention. Biochem. Soc. Trans., 2005, 33(Pt 5), 1087-1090.
34. Maezawa, I.; Hong, H. S.; Liu, R.; Wu, C. Y.; Cheng, R. H.; Kung, M. P.; Kung, H. F.; Lam, K. S.; Oddo, S.; Laferla, F. M.; Jin, L. W. Congo red and thioflavin-T analogs detect Abeta oligomers. J. Neurochem., 2008, 104(2), 457-468.
35. Sadowski, M.; Pankiewicz, J.; Scholtzova, H.; Tsai, J.; Li, Y.; Carp, R. I.; Meeker, H. C.; Gambetti, P.; Debnath, M.; Mathis, C. A.; Shao, L.; Gan, W. B.; Klunk, W. E.; Wisniewski, T. Targeting prion amyloid deposits in vivo. J. Neuropathol. Exp. Neurol., 2004, 63(7), 775-784. (Pubitemid 38891093)
36. Brendza, R. P.; Bacskai, B. J.; Cirrito, J. R.; Simmons, K. A.; Skoch, J. M.; Klunk, W. E.; Mathis, C. A.; Bales, K. R.; Paul, S. M.; Hyman, B. T.; Holtzman, D. M. Anti-Abeta antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice. J. Clin. Invest., 2005, 115(2), 428-433.
37. Meyer-Luehmann, M.; Spires-Jones, T. L.; Prada, C.; Garcia- Alloza, M.; de Calignon, A.; Rozkalne, A.; Koenigsknecht-Talboo, J.; Holtzman, D. M.; Bacskai, B. J.; Hyman, B. T. Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature, 2008, 451(7179), 720-724.
38. Dodart, J. C.; Bales, K. R.; Gannon, K. S.; Greene, S. J.; DeMattos, R. B.; Mathis, C.; DeLong, C. A.; Wu, S.; Wu, X.; Holtzman, D. M.; Paul, S. M. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat. Neurosci., 2002, 5(5), 452-457.